The purpose of the Animal Imaging Core (Core E) is to support the translational research objectives of the SPORE by (1) providing imaging support for studies of prostate tumor models, and (2) investigating preclinical models for developing, testing, and validating new treatments, both genetic and chemotherapy, to enhance treatment of prostate cancer. The Animal Imaging Core is responsible for the following: - Support state-of-the-art MR, PET, and optical imaging facilities for optimal small-animal imaging studies - Develop technical methods to optimize MR and PET studies - Provide magnetic resonance spectroscopy (MRS), optical and radionuclide imaging to support preclinical pilot studies in the Developmental Research Program (DRP) - Development and validation of imaging biomarkers

Public Health Relevance

As transgenic and knockout rodent models of have been developed that are increasingly more accurate in modeling human disease, the ability to track these tumor models longitudinally is essential. With laboratory access to such clinical modalities as MRI, PET, CT, SPECT, etc., the results of small-animal imaging are immediately relevant to the SPORE in Prostate Cancer and for translation to the clinic.

Agency
National Institute of Health (NIH)
Type
Specialized Center (P50)
Project #
5P50CA092629-14
Application #
8730094
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
Budget End
Support Year
14
Fiscal Year
2014
Total Cost
Indirect Cost
City
New York
State
NY
Country
United States
Zip Code
10065
Loeb, Stacy; Lilja, Hans; Vickers, Andrew (2016) Beyond prostate-specific antigen: utilizing novel strategies to screen men for prostate cancer. Curr Opin Urol 26:459-65
Fleshner, Katherine; Assel, Melissa; Benfante, Nicole et al. (2016) Clinical Findings and Treatment Outcomes in Patients with Extraprostatic Extension Identified on Prostate Biopsy. J Urol 196:703-8
Carlsson, Sigrid V; de Carvalho, Tiago M; Roobol, Monique J et al. (2016) Estimating the harms and benefits of prostate cancer screening as used in common practice versus recommended good practice: A microsimulation screening analysis. Cancer 122:3386-3393
Zelefsky, Michael J; Poon, Bing Ying; Eastham, James et al. (2016) Longitudinal assessment of quality of life after surgery, conformal brachytherapy, and intensity-modulated radiation therapy for prostate cancer. Radiother Oncol 118:85-91
Kent, Matthew; Penson, David F; Albertsen, Peter C et al. (2016) Successful external validation of a model to predict other cause mortality in localized prostate cancer. BMC Med 14:25
Scher, Howard I; Lu, David; Schreiber, Nicole A et al. (2016) Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer. JAMA Oncol 2:1441-1449
Sood, Anup; Miller, Alexandra M; Brogi, Edi et al. (2016) Multiplexed immunofluorescence delineates proteomic cancer cell states associated with metabolism. JCI Insight 1:
Danila, Daniel C; Samoila, Aliaksandra; Patel, Chintan et al. (2016) Clinical Validity of Detecting Circulating Tumor Cells by AdnaTest Assay Compared With Direct Detection of Tumor mRNA in Stabilized Whole Blood, as a Biomarker Predicting Overall Survival for Metastatic Castration-Resistant Prostate Cancer Patients. Cancer J 22:315-320
Braun, Katharina; Sjoberg, Daniel D; Vickers, Andrew J et al. (2016) A Four-kallikrein Panel Predicts High-grade Cancer on Biopsy: Independent Validation in a Community Cohort. Eur Urol 69:505-11
Preston, Mark A; Batista, Julie L; Wilson, Kathryn M et al. (2016) Baseline Prostate-Specific Antigen Levels in Midlife Predict Lethal Prostate Cancer. J Clin Oncol 34:2705-11

Showing the most recent 10 out of 424 publications